|
Autologous CD19-BCMA Dual-Target CAR T-Cell Therapy Clinical Trials
1 actively recruiting trial
Pipeline
Phase 1: 1
Top Sponsors
- Beijing Boren Hospital1
Indications
- Relapsed/Refractory Multiple Sclerosis1
- Relapsed/Refractory Autoimmune Hemolytic Anemia1
- Relapsed/Refractory sjögren's Syndrome1
- Relapsed/Refractory Idiopathic Inflammatory Myopathies1
- Relapsed/Refractory Systemic Sclerosis1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.